On April 29, the FDA Oncology Drug Advisory Committee voted 22-1 to recommend approval of Amgen’s talimogene laherparepvec (T-VEC) for the treatment of patients with advanced melanoma. Continue reading

On April 29, the FDA Oncology Drug Advisory Committee voted 22-1 to recommend approval of Amgen’s talimogene laherparepvec (T-VEC) for the treatment of patients with advanced melanoma. Continue reading
Memorial Sloan Kettering has started testing the cancers of its patients for 341 cancer-related genes. It is collaborating with Quest Diagnostics to perform the analyses in an effort to identify biomarkers that can best guide appropriate therapy. This is precision medicine, and it is happening at other major cancer centers, as well… Continue reading